James L. Vincent, chairman and chief executive officer ofBiogen Inc., announced Tuesday at H&Q that Biogen hasreceived notice of a patent allowance for Hirulog, itscardiovascular drug. Vincent also said that Biogen will begin aPhase III clinical trial for Hirulog in angioplasty.
Revenues for the Cambridge, Mass., company in 1992 areexpected to exceed $135 million, according to Vincent, withearnings per share to exceed $1.10. BiogenLs stock(NASDAQ:BGEN) closed Tuesday at $43.50, down $1.75 pershare.
(c) 1997 American Health Consultants. All rights reserved.